Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine ...

Novo Nordisk (NYSE:NVO) announced on Tuesday that Maziar Mike Doustdar will become its new president and chief executive ...

Delhi: Global healthcare major Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new President and ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer, to be ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of ...

On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE: NVO) following the announcement of a CEO transition. Analysts view the ...

Novo Nordisk's stock is still up more than 250% since Jørgensen took over as CEO in January 2017. But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took ...